Archive:
Jan 24, 2022, 12:00 AM
ZetaMet Receives Health Canada Authorization For Phase 2A Study In Treating Metastatic Bone Lesions
January
24,
2022
Press Release provided by Zetagen
January 18th, 2022, (Syracuse New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and…
Read More »